FRANCE – Withings, a leader in connected health technology, has secured approximately US $22.5 million in investment from the French government to support its new initiative, Project DEEP (DEvice as a hEalth Prevention platform).
Part of the France 2030 initiative, this project is focused on harnessing cutting-edge AI and medical device innovation to transform the early detection and prevention of cardiometabolic diseases like diabetes, hypertension, and atrial fibrillation (AFib).
Empowering the future of healthcare with technology
The France 2030 initiative, a US $56.6 billion investment strategy by the French government, aims to position France as a leader in innovation, particularly in the digital healthcare sector.
Withings’ Project DEEP will play a crucial role in driving this vision forward by developing advanced, non-invasive medical devices designed to detect cardiometabolic pathologies in their earliest stages.
Eric Carreel, Chairman and Founder of Withings, shared, “With the surge in cardiometabolic diseases burdening healthcare systems, technological innovation and AI research are pivotal in transitioning to a preventive care model.”
He emphasized the critical role of Project DEEP in addressing these diseases before they escalate into serious complications such as stroke, myocardial infarction, and amputations.
“France 2030’s support underscores the importance of empowering French companies like Withings to lead globally in this transformation,” Carreel said.
A Preventive approach to healthcare
Project DEEP represents a milestone in the fight against diseases that are placing a significant strain on healthcare systems worldwide.
By utilizing AI-driven algorithms, Withings aims to create tools that go beyond traditional diagnosis, offering scalable, proactive care tailored to individual health profiles.
This approach could reduce the long-term burden on healthcare providers by preventing diseases from reaching critical stages that require costly interventions.
The company’s existing portfolio of connected health devices—including smart scales, blood pressure monitors, watches, sleep analyzers, and urine analyzers—is already making waves in the digital health space.
Combining AI with these devices, Withings plans to create a more integrated, personalized health ecosystem.
The initiative aims to empower patients with actionable insights, enabling early detection and management of chronic conditions from the comfort of their own homes.
“Withings’ AI-driven solutions will not only enhance existing products but also pave the way for groundbreaking medical devices and solutions that we have yet to imagine,” Carreel added.
Catalyzing global change in cardiometabolic health
The funding from France 2030 will also accelerate Withings’ R&D efforts over the next five years, enhancing the company’s capabilities in the development of cutting-edge medical devices.
While Withings currently focuses on consumer health devices, Project DEEP’s potential extends beyond the individual, with plans to explore partnerships with healthcare providers to integrate its technology into clinical environments.
As Withings continues to build on its legacy of innovation, this investment represents not only a step forward in preventive healthcare but also an opportunity for global collaboration.
Through Project DEEP, Withings intends to drive a global transition to a preventive care model, making a lasting impact on the way cardiometabolic diseases are managed and treated worldwide.
“By developing the tools to detect and manage these diseases earlier, we can help prevent the long-term complications that often result in expensive treatments and hospitalizations,” Carreel noted.
